The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.” TOKYO and CAMBRIDGE, England , Dec. About Sosei Heptares.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience? Vigil Neuroscience. Led by industry veteran Ivana Magov?evi?-Liebisch

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

The Pharma Data

JANUARY 10, 2021

Then, he identified the problem: “Really, what the tumor has done is to figure out a way to hide from the immune system, and all of our therapy has actually been helping that tumor to hide from the immune system. The last year, I think, is a very exciting year for cell therapy against cancer. NK Cells Locked, Loaded, and Ready to Fire.

Vaccine 52

Vaccine Disease Regulations Small Molecule 52

The Pharma Data

AUGUST 5, 2021

The transaction was announced on July 19, 2021. The acquisition strengthens BioNTech’s cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program. Kite’s singular focus is cell therapy to treat and potentially cure cancer.

Therapies 52

Therapies Small Molecule Vaccine Science 52

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research DNA 52

The Pharma Data

JANUARY 19, 2021

With this kind of a start, 2021 may be scorching. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. TCR2 Therapeutics – The Cambridge, Mass.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:16 UTC. Patent US10835501B2 Begins Development of Indication BioSciences’ Intellectual Patent Portfolio for statin plus cannabinoid combination therapies. Current statin therapies are associated with adverse effects including myalgia. Issuance of U.S. SILVERTHORNE, Colo.–(

Small Molecule 52

Small Molecule Therapies Clinical Research Pharmaceuticals 52

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. As a result, we expect a 50-60% year-over-year Parsabiv sales decline in 2021.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS –(BUSINESS WIRE)– Kite Pharma, Inc., to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. Kite’s manufacturing facility in El Segundo, California, U.S.

Therapies 40

Therapies Marketing Small Molecule Science 40

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

Drug Target Review

JULY 7, 2023

There is a clear need for new and approved, safe, effective and innovative targeted therapies to address the underlying causes of autoantibody diseases. The power of precision therapy Targeted — or precision — therapy, a technique that has been honed for many years in cancer treatment, is now being applied in a wider context.

Disease 98

Disease Immune Response Therapies Treatment 98

Drug Target Review

JUNE 12, 2023

TEAD proteins are known to be very important in cancer progression TEAD proteins are known to be very important in cancer progression, and there are a number of therapies in development. 2021 – and a robust pipeline that includes 3 AI-designed drugs (for IPF, COVID-19 and cancer) currently in clinical trials.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

JANUARY 25, 2021

26, 2021 13:00 UTC. –( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

The Pharma Data

MARCH 25, 2021

The study evaluated the safety and efficacy of two doses of abrocitinib, 100mg and 200mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy. The manuscript was published in the March 25, 2021 issue of NEJM. Both doses of abrocitinib met the co-primary study endpoints.

Small Molecule 52

Small Molecule Therapies Treatment Disease 52

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. The company hopes to follow vibegron to the market with URO-902, a novel gene therapy for patients whose OAB has eluded oral pharmacologic therapy.

Science 52

Science Small Molecule FDA Approval Therapies 52

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

JANUARY 18, 2021

18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. © 2021 Sorrento Therapeutics, Inc. SAN DIEGO, Jan.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JULY 15, 2021

The company’s proprietary chemical biology-based platform enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules. There will be no change to Lilly’s 2021 non-GAAP earnings per share guidance as a result of this transaction. Aquilo Partners, L.P.

Small Molecule 52

Small Molecule Engineering Therapies Science 52

The Pharma Data

SEPTEMBER 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. Transaction Terms.

FDA Approval 52

FDA Approval Therapies Small Molecule FDA 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — AIkido Pharma Inc. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?,

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

The Pharma Data

JANUARY 13, 2021

14, 2021 11:00 UTC. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

JANUARY 5, 2021

06, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients.

Small Molecule 40

Small Molecule Therapies Drugs 40

The Pharma Data

JANUARY 17, 2021

The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. We will continue to collaborate with the FDA during their review process and in parallel build our commercial readiness for a potential approval and commercial launch in the first quarter of 2021.”.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

JANUARY 7, 2021

Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. ET Today.

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

NIH Director's Blog: Drug Development

OCTOBER 11, 2022

For clinical researchers, click chemistry has emerged as a workhorse in drug discovery and the improved targeting of cancer chemotherapies and other small-molecule drugs. The approach also is being used to improve delivery of antibody-based therapies and to create new biomaterials. Kolb, HC, Finn, MG, Sharpless, KB.

Research 52

Research Small Molecule Science Clinical Research 52

The Pharma Data

JANUARY 13, 2021

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021. 14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. WO 2021/001458 A1. We are developing the manufacturing processes for TNX-1500 and expect Good Manufacturing Practice (GMP) TNX-1500 to be available in the third quarter of 2021.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 14, 2021

14, 2021 /PRNewswire/ — Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence (“A.I.”) The offering is expected to close on January 20, 2021 , subject to satisfaction of customary closing conditions. DALLAS , Jan.

Small Molecule 52

Small Molecule Therapies Drug Development Drugs 52

The Pharma Data

JANUARY 19, 2021

20, 2021 (GLOBE NEWSWIRE) — Neuronascent Inc. , This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers. CLARKSVILLE, Md., There is a great need for a disease-modifying treatment for the 5.3

Disease 40

Disease Small Molecule Clinical Trials Therapies 40

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 10, 2021

11, 2021 /PRNewswire/ — On January 8, 2021 , Shenzhen Chipscreen Biosciences Co., Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. SHENZHEN, China , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

The Pharma Data

DECEMBER 20, 2020

The therapy is a combination of anticoagulant, anti-inflammatory and antiviral effects. It hopes to include more than 4,000 people in additional trials, with a possible regulatory approval by the fourth quarter of 2021. The first trial site has been opened and the rest will open in 2021. FLT180a is an AAV gene therapy.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

JANUARY 8, 2021

When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space. Its application has the potential to enable smaller and faster trials, and thus deliver innovative therapies to a broad population years faster than otherwise would be possible.

Clinical Trials 52

Clinical Trials Small Molecule Trials Disease 52

The Pharma Data

JANUARY 6, 2021

7, 2021 11:00 UTC. Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021. Taladegib is a small-molecule inhibitor of the Hedgehog signaling pathway. About Endeavor BioMedicines.

Disease 40

Disease Small Molecule Treatment Therapies 40

The Pharma Data

JANUARY 3, 2021

Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. million, with the majority to be completed by the first quarter of 2021. More financial details will be provided by the company in its fourth quarter 2020 financial report in March 2021. SOUTH SAN FRANCISCO, Calif.,

Trials 52

Trials Clinical Trials Small Molecule Therapies 52